Pharmacological activity of the hydroalcoholic extract from *Hovenia dulcis* thunberg fruit and the flavonoid dihydromyricetin during hypercholesterolemia induced in rats

Juliana Tensol Pinto¹,*; Tânia Toledo de Oliveira¹, Luana Farah Alvarenga¹, Adriano Simões Barbosa¹, Virginia Ramos Pizziolo¹, Marcelo Rocha da Costa¹

Departament of Biochemistry and Molecular Biology, Federal University of Viçosa

Cerebrovascular accidents and coronary artery disease are the leading causes of cardiovascular mortalities in Brazil and high levels of LDL cholesterol are one of the main risk factors. In this context, several plant extracts and natural substances have shown promise as cholesterol-lowering. The objective of this study was to evaluate the potential of the hydroalcoholic extract of the fruit of *H. dulcis* and of dihydromyricetin in cholesterol reduction in hypercholesterolemic rats. Forty-two Wistar male rats were distributed into seven groups of six animals that received diets supplemented with 1% cholesterol and 0.3% cholic acid, with the exception of the control group, which received conventional diets. Animals were treated with oral suspensions containing: atorvastatin 1.0 mg/kg; *H. dulcis* extract at 50.0 and 100.0 mg/kg and dihydromyricetin at 25.0 and 50.0 mg/kg vehicle (control group). The following biochemical markers were evaluated; total cholesterol, HDL-C, LDL-C, triglycerides, AST, ALT, and alkaline phosphatase. The hypercholesterolemic diet was effective in inducing hypercholesterolemia, increasing total cholesterol by 112.7% relative to the control group. The treatments with two doses of the extract proved to be promising hypocholesterolemic agents, as they were able to substantially reduce total cholesterol and LDL-C, without significantly altering triglycerides, hepatic transaminases, and alkaline phosphatase, thereby encouraging the studies with the plant *H. dulcis*. The groups treated with the flavonoid dihydromyricetin, although they showed a significant reduction in total cholesterol and LDL-C, and found increases in triglycerides and hepatic transaminases, which is unwanted in the context of hypercholesterolaemia.


No Brasil, o acidente vascular cerebral e a doença arterial coronariana constituem as principais causas de mortalidade cardiovascular, sendo os altos níveis de colesterol LDL um dos principais fatores de risco. Nesse contexto, diversos extratos vegetais e substâncias naturais isoladas têm se mostrado promissoras como hipocolesterolemiantes. O objetivo do trabalho foi avaliar o potencial do extrato hidroalcoólico dos frutos de *Hovenia dulcis* e do flavonóide diidromiricetina na redução do colesterol em ratos hipercolesterolêmicos. Quarenta e dois ratos Wistar machos, foram distribuídos em 7 grupos de 6 animais, que receberam dieta suplementada com 1% de colesterol e 0,3% de ácido cólico, à exceção do grupo controle, que recebeu ração convencional. Posteriormente, os animais foram tratados com suspensões orais contendo: atorvastatina 1,0 mg/kg; extrato de *H. dulcis* de 50,0 e 100,0 mg/kg; diidromiricetina de 25,0 e 50,0 mg/kg e veículo (grupo controle). Avaliaram-se os parâmetros bioquímicos: colesterol total, HDL-C, LDL-C, triglicérides, AST, ALT e fosfatase alcalina. A dieta hipercolesterolêmica foi efetiva na indução da hipercolesterolemia, aumentando o colesterol total em 112,7% em relação ao controle. Os tratamentos com as duas doses do extrato mostraram-se promissores como agentes hipocolesterolemiantes, já que foram capazes de reduzir substancialmente o colesterol

*Correspondence: J. T. Pinto. Laboratório Biofármacos, Universidade Federal de Viçosa-MG, Campus Universitário, Vila Gianetti, casa 26, 36570-000 – Viçosa – MG, Brasil. E-mail: jutensol@yahoo.com.br
total e LDL-C, sem alterar significativamente triglicérides, as transaminases hepáticas e a fosfatase alcalina, incentivando, assim, a continuidade de estudos com a planta *H. dulcis*. Já os grupos tratados com o flavonóide dihidromiricetina, apesar de apresentarem redução significativa do colesterol total e de LDL-C, apresentaram elevações nos triglicérides e nos parâmetros hepáticos, resultado indesejável no âmbito das hipercolesterolemias.


---

**INTRODUCTION**

In Brazil, the latest DATASUS data showed that stroke and coronary artery disease are the leading causes of cardiovascular mortality. The IV Brazilian Guidelines on Dyslipidemia and Atherosclerosis Prevention (2007) points out that the relative risk of cardiovascular events increases with various risk factors, including hypercholesterolemia (blood cholesterol levels greater than 200 mg/dL).

Several studies consider high levels of LDL cholesterol as an important risk factor of coronary artery disease and cardiovascular disease in different populations. (Khoo *et al.*, 2013; Tonelli *et al.*, 2013; Schaefer *et al.*, 2013).

According to the IV Brazilian Guidelines on Dyslipidemia and Atherosclerosis Prevention of the Society of Cardiology (2007), there has been a decline in mortality from cardiovascular causes in developed countries in the past 30 years. However, in developing countries, including Brazil, there has been a relatively rapid and substantial increase.

Studies have shown that plant extracts containing antioxidants or isolated compounds capable of reversing oxidative stress present in hypercholesterolemia can be promising as adjuvant therapy (Negi, Kaur, Dey, 2013; Dai *et al.*, 2013; Al-Rejaie *et al.*, 2013).

According to the IV Brazilian Guidelines on Dyslipidemia and Atherosclerosis Prevention of the Society of Cardiology (2007), there has been a decline in mortality from cardiovascular causes in developed countries in the past 30 years. However, in developing countries, including Brazil, there has been a relatively rapid and substantial increase.

The effect of antioxidants on hypercholesterolemia are attributed to their capacity of increasing the LDL-C resistance to oxidation and, therefore, to reduce the risk of cardiovascular disease. *In vitro* studies showed that the LDL oxidation only starts after the oxidative stress has depleted the contents of cellular antioxidants (Jessup *et al.*, 1990).

*Hovenia dulcis* is popularly known in Brazil mainly by “uva-do-japão” (Japanese RaisinTree in English) (Carvalho, 1994). This species is used in traditional Chinese and Korean medicine for alcohol detoxification (Chen *et al.*, 2006; Fang *et al.*, 2007; Hase *et al.*, 1997) and as a hypoglycemic agent (Jeong-sang, Chang-soo, Jong-bang, 2005; Ji *et al.*, 2002; Lee, Chae, Moon, 2005).

The Provital Group (2006) published results from *in vitro* and *in vivo* studies demonstrating the effectiveness of Myriceline® (Dihydromyricetin) to reduce cellulite in the skin. The *in vitro* assays detected action of dihydromiricetin on adipogenesis, lipolysis and lipogenesis.

Fang *et al.* (2007) reported high levels of phenolic compounds in the alcoholic extract of *H. dulcis* fruits. They also found high antioxidant activity using the DPPH method, and related this activity to the phenolic compounds present in the extract, mainly to flavonoids. Zhang *et al.* (2003) demonstrated that dihydromiricetin has high DPPH (1,1-diphenyl-2-picrylhydrazyl)-radical scavenging activity and strong inhibitory action of lipid peroxidation.

The induction of hypercholesterolemia in rats is widely used. In the study of Yokozawa *et al.* (2006), a diet supplemented with 1% cholesterol and 0.5% cholic acid led to increases of 65.7% and 80% in the rates of total cholesterol and LDL, respectively, in rats. However, Machado *et al.* (2003) obtained moderate hypercholesterolemia (49%) using a diet supplemented with 1% cholesterol and 0.1% cholic acid. Afonso *et al.* (2013), using a diet containing 0.5% cholesterol and 0.25% cholic acid reached an extreme state of hypercholesterolemia with an increase of 297% in total cholesterol.

However, up to date, no studies have been found that have investigated the hypothesis of the plant or the flavonoid dihydromyricetin. Nevertheless, studies from our research group (Alvarenga, 2008) evaluating the effect of *H. dulcis* extract and dihydromyricetin in alloxan-induced diabetic rabbits showed, among other results, reduction in total cholesterol and LDL-C and increase in HDL-C, suggesting the need to study the plant and the flavonoid on a specific model of hypercholesterolemia.

The objective of this study was to evaluate the potential of the hydroalcoholic extract of the fruit of *H. dulcis* and of dihydromyricetin in cholesterol reduction in hypercholesterolemic rats.
MATERIAL AND METHODS

Processing of plant material

*H. dulcis* fruits were collected from an adult tree, located in the city of Perdôes, Minas Gerais State, Brazil (21º05´38.51˝S and 45º05´24.75˝) in January 2009. Exsiccate was deposited in the José Badini-UFOP Herbarium (OUPR 21003). The fruits were dried in an oven with forced air ventilation at 40 ºC to a constant weight, ground and remacerated in ethanol/water 1:1, until the material was exhausted (Sonaglio *et al.*., 2004). The obtained extract was dried in a rotary evaporator at reduced pressure and subsequently lyophilized, then stored in an ultrafreezer (-80 ºC).

Test suspensions

An inert suspension (vehicle) was used to incorporate the principal additives of atorvastatin, dihydromyricetin synthetic (Provital group®, lot 501435) and lyophilized hydroalcoholic *H. dulcis* extract in their respective dosages. The composition of the vehicle was: Propilenoglicol (20%); suspending agent Suspender® (1.5%); preservatives Nipagim (0.1%) / Nipasol (0.05%) and distilled water q.s.p. 100%.

Feeding protocol

The commercial rodent diet (Presence®) was ground in a hammer mill, at 3200 rpm, with a 0.25 mm sieve (Inbramaq). A portion of the pulverized commercial food was reserved for the control diet.

Simultaneously, cholesterol (Vetec®, lot 1101904) and cholic acid (Sigma-Aldrich®, lot 031M1781V) were weighed in quantities sufficient for final product content of 1.0% of the former and 0.3% of the latter. The additives were mixed manually into the pulverized diet by geometric dilution. Afterward, the mixture was placed in a mixer for 15 minutes for further homogenization. The mixture was then placed in an Imbramaq MX-40 extruder/pelletizer under the following settings: supply velocity of 20 kg/h; humidity of 10ccH₂O/cm³; cutting frequency 32.5 Hz; matrix of 5 mm in diameter, maximum temperature of 50 ºC for pellet confection. Pellets were dried in an Inbramaq horizontal drier at 50 ºC. After cooling, the pellets were packaged into waterproof plastic bags. The pulverized control diet was processed with the same pelletization procedure and dried as already described, in order to have the same physical and chemical characteristics and digestibility of the hypercholesterolemic diet.

**Experiments in vivo**

The *in vivo* evaluation of pharmacological activity was based on the studies of Machado *et al.* (2003) and Afonso *et al.* (2013). The use of laboratory animals in this study was previously approved by the Ethics Committee on Animal Experimentation of the Biological Sciences and Health Faculty (FACISA-Viçosa/MG, Protocol 0017/2012-1).

Forty two (42) male rats (*Rattus novergicus*, var. *albinus*) of the Wistar lineage, approximately 5 weeks old, weighing an average of 138.7 ± 11.85 g, were acquired from the Vivarium for Animal Experimentation of the Veterinary Medicine Department of the Federal University of Viçosa and distributed randomly among 7 groups of 6 animals, housed in cages with an air exhaust system, temperature of 22 ± 5 ºC, and relative humidity of 55 ± 10% and light/dark cycle of 12 hours.

After a habituation period of 5 days, during which the animals ingested the control diet (non-hypercholesterolemic), the animals received a hypercholesterolemic diet over the next 10 days (with the exception of group 1 which remained on the control diet). Starting on the 11th day, treatment began with the test substances and the animals maintained the same diet until Table I - Experimental groups

<table>
<thead>
<tr>
<th>GROUPS</th>
<th>CODE</th>
<th>TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>C</td>
<td>Control diet, treated with inert vehicle.</td>
</tr>
<tr>
<td>Group 2</td>
<td>HC</td>
<td>Hypercholesterolemic diet, treated with inert vehicle.</td>
</tr>
<tr>
<td>Group 3</td>
<td>ATOR</td>
<td>Hypercholesterolemic diet, treated with atorvastatin 1.0 mg/kg.</td>
</tr>
<tr>
<td>Group 4</td>
<td>DHM 1</td>
<td>Hypercholesterolemic diet, treated with dihydromyricetin 25.0 mg/kg.</td>
</tr>
<tr>
<td>Group 5</td>
<td>DHM 2</td>
<td>Hypercholesterolemic diet, treated with dihydromyricetin 50.0 mg/kg.</td>
</tr>
<tr>
<td>Group 6</td>
<td>EHD 1</td>
<td>Hypercholesterolemic diet, treated with <em>H. dulcis</em> extract 50.0 mg/kg.</td>
</tr>
<tr>
<td>Group 7</td>
<td>EHD 2</td>
<td>Hypercholesterolemic diet, treated with <em>H. dulcis</em> extract 100.0 mg/kg.</td>
</tr>
</tbody>
</table>
day 30. The compounds tested were delivered by gavage in 0.5 mL, daily at 6:00 pm.

**Euthanasia and biochemical dosages**

The animals were euthanized in a carbon dioxide chamber (40% in atmospheric air under slow administration). The animals were then immediately subject to cardiac perfusion for blood collection. Using the animals’ serum, biochemical dosages were analyzed with a Cobas Mira Plus (Roche®) instrument. The concentrations of total cholesterol (COT), triglycerides (TG) and serum high density lipoprotein (HDL-C) were determined by enzymatic colorimetric analysis, using a biochemical kit for each respective analysis. Low density lipoprotein (LDL-C) was calculated according to the formula LDL= COT - HDL - (TG/5), as described by Friedwald, Levy and Fradrickson (1972). Concentrations of aminotransferase alanine (ALT), aspartatoaminotransferase (AST), and alkaline phosphatase (FALC) were determined by the kinetic method using a biochemical kit.

**Statistical analysis**

Analysis of variance (ANOVA), was calculated, followed by a Dunnett test with a level of significance set at p<0.05, using group HC as the reference group, using the program SAEG 9.1.

**RESULTS AND DISCUSSION**

**Induction of hypercholesterolaemia**

A diet supplemented with 1.0% cholesterol and 0.3% cholic acid, for a period of 30 days, was capable of significantly inducing hypercholesterolemia, with observed increases found in serum levels of total cholesterol (COT) (82.66 ± 10.11 mg/dL vs 175.83 ± 6.24 mg/dL) and low density lipoprotein (LDL-C) (30.53 ± 8.95 mg/dL vs 125.16 ± 24.19 mg/dL) along with a reduction in serum levels of high density lipoprotein (HDL) (43.66 ± 2.16 mg/dL vs 35.5 ± 8.21 mg/dL) compared to the control group. Higher results were found by Afonso et al. (2013), who employed a diet supplemented with 0.5% cholesterol and 0.25% cholic acid over a period of 30 days in Wistar rats, for which there was an increase of 297.9%, while in the present study an elevation of 112.7% was observed for the same parameter. On the other hand, in a study done by Yokozawa et al. (2006) a diet supplemented with 1% cholesterol and 0.5% cholic acid showed only a 65.7% increase of total cholesterol. There was no significant difference between food consumption and weight gain by Analysis of variance (Tables II and III).

**Lipid profile**

Table IV shows the average values of analyzed biochemical parameters for the experimental groups on day 30, with their respective significant statistics.

**Total cholesterol**

All treatments significantly reduced levels of total cholesterol (Dunnett, p<0.05) compared to reference group HC, with the largest reduction being seen in the group treated with atorvastatin 1.0 mg/kg, at 40.38%. Groups EHD 1 and EHD 2 had reductions of 22.56 and 33.36%, respectively. Also, the groups treated with the flavonoid (DHM 1 and DHM 2) had a reduction of 19.46 and 17.53%, respectively. It is worthy to note, however, that the doses of the extract and the flavonoid were higher than the medical reference dose of atorvastatin, with the superiority of this substance over the others being unquestionable regarding the reduction of total cholesterol.

In the study of Alvarenga (2008), the hydroalcoholic extract of *H. dulcis* at a dose of 200 mg/kg reduced total cholesterol in diabetic rabbits by 68% over 28 days. It is

<table>
<thead>
<tr>
<th>Groups</th>
<th>Iniical Weight</th>
<th>First week</th>
<th>Second Week</th>
<th>Third Week</th>
<th>Fourth Week</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>149.2</td>
<td>159.2</td>
<td>176.7</td>
<td>200.8</td>
<td>229.2</td>
</tr>
<tr>
<td>HC</td>
<td>134.2</td>
<td>154.2</td>
<td>171.7</td>
<td>198.3</td>
<td>235.0</td>
</tr>
<tr>
<td>ATOR</td>
<td>135.0</td>
<td>150.0</td>
<td>161.7</td>
<td>189.2</td>
<td>220.8</td>
</tr>
<tr>
<td>DHM 1</td>
<td>140.0</td>
<td>156.7</td>
<td>171.7</td>
<td>199.2</td>
<td>225.0</td>
</tr>
<tr>
<td>DHM 2</td>
<td>133.3</td>
<td>154.2</td>
<td>165.8</td>
<td>195.0</td>
<td>218.3</td>
</tr>
<tr>
<td>EHD 1</td>
<td>143.3</td>
<td>163.3</td>
<td>180.0</td>
<td>204.2</td>
<td>230.0</td>
</tr>
<tr>
<td>EHD 2</td>
<td>135.8</td>
<td>155.0</td>
<td>166.7</td>
<td>194.2</td>
<td>216.7</td>
</tr>
</tbody>
</table>
possible to infer that the flavonoid dihydromyricetin has hypocholesterolemic action, but is not the only active factor present in the extract, since administering the extract in a dose of 50.0 mg/kg exhibited a greater reduction than administering the isolated flavonoid at the same dose, indicating the presence of additive synergism between molecules in the extract.

It is known that saponins form insoluble complexes with \( \beta \)-hydroxysteroids, diminishing intestinal absorption of cholesterol and increasing the fecal excretion of sterols (Milgate, Roberts, 1995). In \( H. dulcis \), the presence of saponins in leaves extract were describe by Hogihara et al. (1987) and hydroalcoholic extract of \( H. dulcis \) fruits were describe by Alvarenga (2008). It is still necessary further studies to determine presence of saponins in \( H. dulcis \) and confirm its hypocholesterolemic action.

### LDL-C

All treatments significantly reduced levels of LDL-C (Dunnett, \( p<0.05 \)) compared to reference group HC, with the largest reduction being in the group treated with atorvastatin 1.0 mg/kg, at 68.20%. The groups EHD 1 and EHD 2 had reductions of 40.79 and 51.53%, respectively. Also, groups DHM 1 and DHM 2 had reductions of 45.57 and 37.28%, respectively.

Several mechanisms of action of flavonoids on lipid metabolism have been described. Kothari et al. (2011) reported the increased fecal excretion of cholesterol in hypercholesterolemic rats treated with fresh Triticum aestivum (wheat) grass juice.

Quesada et al. (2009) reported that grape seed proanthocyanidins repress genes controlling lipogenesis and VLDL assembling in liver in rats fed high fat diet. Another mechanism involving transcriptional regulation was described by Goldwasser et al. (2010), which studied the benefits of the flavonoid naringenin on hepatic lipid metabolism in rats.

Brutieridin and melitidin, flavonoids of bergamot juice are structural analogues of statins and were shown to inhibit HMG-CoA reductase the enzyme that catalyzes conversion of HMG-CoA to mevalonate, which is the rate limiting step in the cholesterol synthesis pathway (Leopoldini et al., 2010).

The LDL cholesterol levels reduction is extremely important in hypercholesterolemic individuals, because elevated plasma levels of LDL are highly associated with
appearance of coronary artery disease (Hankey, 2002; Giribela, 2007).

**HDL-C**

The only group ATOR showed a statistically significant rise (Dunnett, p<0.05). Auger et al. (2002) also had similar results when they evaluated the effects of phenolic compounds present in red wine on plasma lipids in hypercholesterolemia hamsters. A significant difference was not found between HDL-C levels of treated and control animals. The same occurred in the work of Hirunpanich et al. (2006) while working with hibiscus and Soares et al. (2005) with ginger, white mulberry and rosemary in hypercholesterolemic rats.

Although treatments for groups DHM 1, DHM 2, EHD 1 and EHD 2 did not generate a significant rise in HDL cholesterol, it is worth noting that the reduction in levels of total cholesterol and LDL cholesterol under circulation also represents an essential step in the prevention of cardiovascular disease (Lecumberri et al., 2007).

**Triglycerides**

Only group DHM 1 differentiating itself statistically, showing a significantly elevated value for this parameter (Dunnett p<0.05).

According to the IV Brazilian Guidelines on Dyslipidemia and Prevention of Atherosclerosis (2007), accumulation of chylomicrons and VLDL in the plasma compartment results in hypertriglyceridemia and stems from a decrease in triglyceride hydrolysis of these lipoproteins by lipoprotein lipase or from increased synthesis of VLDL, since these lipoproteins are rich in triglycerides.

Given the above, we postulate that treatment with DHM 1 (dose of 25.0 mg/kg) produced a negative result within the context of hypercholesterolemas, as although there was a significant reduction in total cholesterol and LDL-c, the treatment promoted a significant increase in triglycerides.

In Afonso et al. (2013), an aqueous extract of rosemary at a concentration of 70 mg/kg was able to significantly reduce levels of total cholesterol (39.8%) and LDL-c (45.6%), but positive effects for triglycerides and HDL-C were not observed.

Cherem et al. (2007) subjected guinea pigs to a high-fat diet with and without the addition eggplant peels, and their study showed a reduction in levels of total cholesterol and LDL-cholesterol, at 45 and 54%, respectively. A positive effect on triglycerides levels was not observed.

**AST, ALT and alkaline phosphatase**

As the liver is considered the main organ responsible for the maintenance of cholesterol homeostasis, the activity of enzymes indicative of liver lesions, alanine aminotransferase and aspartate aminotransferase, was determined (see Table V).

**TABLE V - Average values ± standard deviation of the parameters AST, ALT and Alkaline Phosphatase (FALC)**

<table>
<thead>
<tr>
<th>Groups</th>
<th>AST (U/L)</th>
<th>ALT (U/L)</th>
<th>FALC (U/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>170.8±23.8</td>
<td>47.2±5.1</td>
<td>158.0±20.4</td>
</tr>
<tr>
<td>HC</td>
<td>151.5±41.7</td>
<td>45.7±3.9</td>
<td>216.8±30.1</td>
</tr>
<tr>
<td>ATOR</td>
<td>130.3±19.8</td>
<td>41.2±8.9</td>
<td>192.2±21.2</td>
</tr>
<tr>
<td>DHM 1</td>
<td>156.0±11.1</td>
<td>71.8±28.4 *</td>
<td>259.2±63.1</td>
</tr>
<tr>
<td>DHM 2</td>
<td>121.0±20.3</td>
<td>48.2±8.1</td>
<td>341.8±70.7 *</td>
</tr>
<tr>
<td>EHD 1</td>
<td>122.0±15.2</td>
<td>56.2±13.8</td>
<td>268.3±28.3</td>
</tr>
<tr>
<td>EHD 2</td>
<td>131.8±14.2</td>
<td>53.0±9.9</td>
<td>245.5±40.2</td>
</tr>
</tbody>
</table>

Values marked with an asterisk (*) in the table, differ from group HC, at a significance level of 95% (p<0.05), when compared using Dunnett’s test.

The results show a significant increase in ALT for the group treated with dihydromyricetin at a dose of 25.0 mg/kg. Nevertheless, we observed that the group treated with a larger dose of dihydromyricetin (50.0 mg/kg) did not show this profile. Such a result can indicate hepatotoxicity or could be attributed to a rise in total lipids, especially triglycerides, a parameter significantly augmented in this group.

The hepatoprotective action of Hovenia dulcis has been a focus of other studies. Hase et al. (1997) found liver-protecting action of H. dulcis fruits methanolic extract, acting on CCl4 toxicity induced in rats and D-GalN/LPS in mice. The animals were treated with 100 mg/kg of extract twice a week for one week before hepatic toxicity induction. Alvarenga (2008) observed a 72% reduction of the AST over 28 days, by treating diabetic rabbits with H. dulcis extract at a 200 mg/kg dose.

In the present study there was no statistically significant difference in AST for the groups treated with the extract (EHD) compared to the control (Dunnett, p<0.05).

In Alkaline Phosphatase, DHM 2 had values significantly higher than HC. This suggests the necessity of conducting histopathological analysis to investigate hepatotoxicity. Alkaline hyperphosphatemia occurs in intrahepatic obstruction in hepatocellular carcinoma, hepatitis, cirrhosis, and through the effect of various
Pharmacological activity of the hydroalcoholic extract from *Hovenia dulcis*

drugs (antifungals, benzodiazepines, steroids and antihypertensives). Its activity can increase two to three times during intrahepatic obstruction (Motta, 2003).

**CONCLUSIONS**

The *H. dulcis* extract treatments can be promising as hypocholesterolemic agents, especially when used in higher doses (100.0 mg/kg), with a substantial Total Cholesterol and LDL-C reduction of 33.3% and 51.5%. There was no increase in the levels of triglycerides and HDL-C found in plasma.

In the dihydromiricetina (25.0 mg/kg) group there was a significant increase in triglycerides, which was an unwanted result when treating hypercholesterolemia.

Further studies should be encourage to determine the exact mechanism of action and toxicity of the *H. dulcis* extract and its pharmacological effects in hypercholesterolemia, so it could be safely used as an option in the future.

**REFERENCES**


Received for publication on 16th January 2013
Accepted for publication on 19th November 2013